Recent studies have discovered that stem cell markers, such as doublecortin-like kinase (DCLK1) and RNA modification by methyltransferase-like 3 (METTL3), play a role in recruitment of CXCR2+ MDSCs to modulate tumor immunity through the CXCL1-CXCR2 axis in CRC mouse models [16, 17]. The gene discussed is DCLK1; the disease is neoplasm.